Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 20/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3539916 | 0.88 | PLA2G7 (0.55) | PLA2G7CYP3A4CYP2D6 | |
| SCHEMBL3612929 | 0.84 | PLA2G7 (0.58) | PLA2G7CYP3A4CYP2D6 | |
| SCHEMBL3542708 | 0.83 | PLA2G7 (0.53) | PLA2G7CYP3A4CYP2D6 | |
| SCHEMBL3540781 | 0.83 | PLA2G7 (0.59) | PLA2G7CYP3A4CYP2D6 | |
| SCHEMBL3538417 | 0.82 | PLA2G7 (0.55) | PLA2G7CYP3A4CYP2D6 | |
| SCHEMBL3539646 | 0.81 | PLA2G7 (0.58) | PLA2G7 | |
| SCHEMBL3537601 | 0.80 | PLA2G7 (0.59) | PLA2G7CYP3A4CYP2D6 | |
| SCHEMBL3534760 | 0.80 | PLA2G7 (0.58) | PLA2G7CYP3A4CYP2D6 | |
| SCHEMBL3534790 | 0.79 | PLA2G7 (0.55) | PLA2G7CYP3A4CYP2D6 | |
| SCHEMBL11932764 | 0.79 | PLA2G7 (0.71) | PLA2G7CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266841-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2016-02-23 | — | — | US | disclosed |
| US-9266841-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2016-02-23 | — | — | US | disclosed |
| US-9266841-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2016-02-23 | — | — | US | disclosed |
| US-20150045375-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-02-12 | — | — | US | disclosed |
| US-20150045375-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-02-12 | — | — | US | disclosed |
| US-20150045375-A1 | NOVEL COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-02-12 | — | — | US | disclosed |
| US-8871775-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2014-10-28 | — | — | US | disclosed |
| US-8871775-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2014-10-28 | — | — | US | disclosed |
| US-8871775-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2014-10-28 | — | — | US | disclosed |
| US-20120172378-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20070155762-A1 | Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an anticholesterol agent; inhibitor of platlet activating factor acetylhydrolase | SMITHKLINE BEECHAM PLC | 2007-07-05 | — | — | US | disclosed |
| US-20070155762-A1 | Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an anticholesterol agent; inhibitor of platlet activating factor acetylhydrolase | SMITHKLINE BEECHAM PLC | 2007-07-05 | — | — | US | disclosed |
| US-20070155762-A1 | Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an anticholesterol agent; inhibitor of platlet activating factor acetylhydrolase | SMITHKLINE BEECHAM PLC | 2007-07-05 | — | — | US | disclosed |
| US-20070123549-A1 | platelet activating factor aceylhydrolase inhibitors such as 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-ethylpyrimidin-4-one; for treatment of atherosclerosis | SMITHKLINE BEECHAM PLC | 2007-05-31 | — | — | US | disclosed |
| US-20070123549-A1 | platelet activating factor aceylhydrolase inhibitors such as 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-ethylpyrimidin-4-one; for treatment of atherosclerosis | SMITHKLINE BEECHAM PLC | 2007-05-31 | — | — | US | disclosed |
| US-20070123549-A1 | platelet activating factor aceylhydrolase inhibitors such as 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-ethylpyrimidin-4-one; for treatment of atherosclerosis | SMITHKLINE BEECHAM PLC | 2007-05-31 | — | — | US | disclosed |
| US-7153861-B2 | For therapy of atheroscelerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-12-26 | — | — | US | disclosed |
| EP-1686119-A1 | PYRIMIDINE-4-ONE DERIVATIVES AS LDL-PLA2 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2006-08-02 | — | — | EP | disclosed |
| EP-1263740-B1 | PYRIMIDINE-4-ONE DERIVATIVE AS LDL-PLA2 INHIBITOR | SMITHKLINE BEECHAM PLC (GB) | 2006-07-19 | — | — | EP | disclosed |
| US-6649619-B1 | 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl) benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimeth ylenepyrimidin-4-one or salt; lipoprotein-associated phospholipase A inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045375-A1 | NOVEL COMPOUNDS | PLA2G7, ALOX15B, PLA2G1B | PLA2G7 1/4885CYP3A4 1950/4885CYP2D6 943/4885 |
| US-20120172378-A1 | NOVEL COMPOUNDS | PLA2G7, ALOX15B, PLA2G1B | PLA2G7 1/4885CYP3A4 1950/4885CYP2D6 943/4885 |
| US-20070155762-A1 | Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an anticholesterol agent; inhibitor of platlet activating factor acetylhydrolase | PLAT, PLA2G7, LYPLAL1 | PLA2G7 2/4885CYP3A4 2423/4885CYP2D6 2804/4885 |
| US-20070123549-A1 | platelet activating factor aceylhydrolase inhibitors such as 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-ethylpyrimidin-4-one; for treatment of atherosclerosis | PLA2G7, PLAT, PLA2G1B | PLA2G7 1/4885CYP3A4 3573/4885CYP2D6 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.